NCT03935984

Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity

Improving the Sensitivity of Sestamibi SPECT-CT Parathyroid Scan with Calcitonin Pre-treatment for Primary Hyperparathyroidism

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 37 (estimated)
• Sponsor: Joseph Sferra · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Patients with biochemically confirmed primary hyperparathyroidism and non-localizing SPECT-CT exam within the past year will be included. Subjects will be treated with calcitonin to lower calcium levels immediately prior to reimaging. The goal of this study is to determine whether lowering calcium will improve uptake/retention of sestamibi and improve sensitivity of SPECT-CT to localize parathyroid adenoma.

Conditions

• Primary Hyperparathyroidism
• Hypercalcemia

Interventions

Type	Name	Description
DRUG	Calcitonin	Treatment with calcitonin to lower high calcium levels prior to reimaging exam

Timeline

• Start date: 2019-05-29
• Primary completion: 2026-06-01
• Completion: 2026-12-31
• First posted: 2019-05-02
• Last updated: 2024-09-19

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study